Lexeo Therapeutics, Inc. - Common Stock ($0.0001 par value) (the "Shares") (LXEO) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2023 to Q4 2025

Type / Class
Equity / Common Stock ($0.0001 par value) (the "Shares")
Symbol
LXEO on Nasdaq
Shares outstanding
74,300,257
Price per share
$7.50
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
76,458,029
Total reported value
$759,168,531
% of total 13F portfolios
0%
Share change
+26,744,100
Value change
+$269,432,782
Number of holders
144
Price from insider filings
$7.50
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Lexeo Therapeutics, Inc. - Common Stock ($0.0001 par value) (the "Shares") (LXEO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 10% -12% $65,914,563 +$10,720,599 7,291,434 +19% JANUS HENDERSON GROUP PLC 28 Nov 2025
BALYASNY ASSET MANAGEMENT L.P. 9.9% -1% $53,656,154 +$13,573,377 7,221,555 +34% Balyasny Asset Management L.P. 31 Dec 2025
CITADEL ADVISORS LLC 7.4% -22% $40,851,767 +$1,219,315 5,498,219 +3.1% Kenneth Griffin 31 Dec 2025
Affinity Asset Advisors, LLC 7.1% -8.1% $51,813,451 +$9,589,340 5,217,660 +23% Affinity Asset Advisors, LLC 22 Jan 2026
RA CAPITAL MANAGEMENT, L.P. 6.9% $33,200,000 5,000,000 RA Capital Management, L.P. 20 Oct 2025
BlackRock, Inc. 6.7% +68% $48,518,087 +$26,984,571 4,885,814 +125% BlackRock, Inc. 31 Dec 2025
Paradigm Biocapital Advisors LP 6.5% +30% $35,390,561 +$8,107,609 4,763,198 +30% Paradigm BioCapital Advisors LP 31 Dec 2025
Vestal Point Capital, LP 7.5% +25% $27,338,885 +$5,903,896 4,117,302 +28% Vestal Point Capital, LP 30 Sep 2025
VANGUARD GROUP INC 5.3% $38,672,056 3,894,310 The Vanguard Group 31 Dec 2025
Frazier Life Sciences Public Fund, L.P. 5.1% -10% $27,478,154 +$4,642,294 3,698,271 +20% Frazier Life Sciences Public Fund, L.P. 31 Dec 2025
Longitude Capital Partners IV, LLC 3.8% $18,362,130 2,765,381 Longitude Capital Partners IV, LLC 30 Sep 2025
INTEGRATED CORE STRATEGIES (US) LLC 3.2% -42% $15,362,583 -$3,470,396 2,313,642 -18% Millennium Management LLC 30 Sep 2025
MIZUHO FINANCIAL GROUP INC 6.6% +13% $8,109,362 +$1,020,464 2,203,631 +14% Mizuho Financial Group, Inc. 31 Mar 2025
EVENTIDE ASSET MANAGEMENT, LLC 3.7% $4,544,189 1,234,834 Eventide Asset Management, LLC 31 Dec 2024
Omega Fund VI, L.P. 3.6% $4,359,460 1,184,636 Omega Fund VI, L.P. 31 Dec 2024
D1 Capital Partners L.P. 2.9% $3,601,439 978,652 D1 Capital Partners L.P. 31 Mar 2025
Adage Capital Management, L.P. 0.7% -85% $875,667 -$7,255,716 237,953 -89% Adage Capital Management, L.P. 31 Mar 2025

As of 31 Dec 2025, 144 institutional investors reported holding 76,458,029 shares of Lexeo Therapeutics, Inc. - Common Stock ($0.0001 par value) (the "Shares") (LXEO). This represents 103% of the company’s total 74,300,257 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Lexeo Therapeutics, Inc. - Common Stock ($0.0001 par value) (the "Shares") (LXEO) together control 90% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
JANUS HENDERSON GROUP PLC 7.4% 5,509,635 -9.8% 0.02% $54,668,943
RA CAPITAL MANAGEMENT, L.P. 6.7% 5,000,000 0.51% $49,650,000
BlackRock, Inc. 6.6% 4,907,563 +126% 0% $48,732,100
Paradigm Biocapital Advisors LP 6.4% 4,763,198 1.3% $47,298,556
Vestal Point Capital, LP 6% 4,475,000 +38% 1.6% $44,436,750
Frazier Life Sciences Management, L.P. 6% 4,424,725 0% 1.2% $43,937,519
VANGUARD GROUP INC 5.2% 3,894,310 +75% 0% $38,670,499
CITADEL ADVISORS LLC 5.1% 3,774,317 +1.5% 0.03% $37,478,968
Avoro Capital Advisors LLC 4.4% 3,300,000 0.32% $32,769,000
Affinity Asset Advisors, LLC 4.3% 3,200,000 -17% 2.3% $31,776,000
Woodline Partners LP 4.3% 3,197,760 +24% 0.12% $31,753,757
STATE STREET CORP 4.3% 3,187,722 +485% 0% $31,654,079
ORBIMED ADVISORS LLC 2.9% 2,125,000 0.45% $21,101,250
Point72 Asset Management, L.P. 2.6% 1,894,722 -2.4% 0.03% $18,814,589
Octagon Capital Advisors LP 2.3% 1,725,000 2.1% $17,129,250
Balyasny Asset Management L.P. 2.2% 1,635,026 -58% 0.03% $16,235,808
GEODE CAPITAL MANAGEMENT, LLC 1.9% 1,445,887 +100% 0% $14,361,075
ADAR1 Capital Management, LLC 1.9% 1,393,161 -9.1% 1% $13,834,089
SUVRETTA CAPITAL MANAGEMENT, LLC 1.7% 1,250,000 0.31% $12,412,500
683 Capital Management, LLC 1.5% 1,120,000 +21% 0.92% $11,121,600
Nantahala Capital Management, LLC 1.3% 1,000,000 0.59% $9,930,000
MILLENNIUM MANAGEMENT LLC 1.2% 908,024 -61% 0.01% $9,016,678
Blackstone Inc. 1.2% 904,959 -20% 0.04% $8,986,243
DIMENSIONAL FUND ADVISORS LP 1.2% 862,892 -5.4% 0% $8,567,932
GOLDMAN SACHS GROUP INC 1.1% 781,855 +449% 0% $7,763,820

Institutional Holders of Lexeo Therapeutics, Inc. - Common Stock ($0.0001 par value) (the "Shares") (LXEO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 76,458,029 $759,168,531 +$269,432,782 $9.93 144
2025 Q3 49,357,693 $327,711,484 +$52,680,502 $6.64 109
2025 Q2 42,272,843 $169,997,165 +$59,022,508 $4.02 90
2025 Q1 28,007,948 $99,996,757 -$11,520,766 $3.47 88
2024 Q4 29,519,159 $194,192,987 -$4,086,062 $6.58 89
2024 Q3 29,735,114 $268,784,046 +$10,322,355 $9.04 67
2024 Q2 26,566,622 $426,105,401 +$55,254,655 $16.04 57
2024 Q1 23,119,889 $361,545,010 +$108,427,159 $15.68 54
2023 Q4 16,174,480 $217,090,546 +$217,090,546 $13.42 31